

The Journal of Clinical Endocrinology & Metabolism
**Letter to the Editor From [Giovanelli] et al.: "DISTINGUISHING SELF-LIMITED
 DELAYED PUBERTY FROM PERMANENT HYPOGONADOTROPIC
 HYPOGONADISM: HOW AND WHY?"**
 --Manuscript Draft--

Manuscript Number:	jc.2021-03109R1
Article Type:	Letter to the Editor
Full Title:	Letter to the Editor From [Giovanelli] et al.: "DISTINGUISHING SELF-LIMITED DELAYED PUBERTY FROM PERMANENT HYPOGONADOTROPIC HYPOGONADISM: HOW AND WHY?"
Corresponding Author:	Luca Giovanelli, M.D. University of Milan, Istituto Auxologico Italiano Milan, ITALY
Corresponding Author's Institution:	University of Milan, Istituto Auxologico Italiano
Order of Authors:	Luca Giovanelli, M.D. Richard Quinton
Additional Information:	
Question	Response
SPECIAL REQUESTS: In place of a cover letter, enter specific comments or requests to the editors here	

Source Files

Il 09/11/21 17:12, **Endocrine Reviews** <em@editorialmanager.com> ha scritto:

You are being carbon copied ("cc'd") on an e-mail "To" "Biagio Cangiano" biagio.cangiano@live.com

CC: "Silvia Federici" silvia.federici@unimi.it, "Giovanni Goggi" giovanni.goggi@unimi.it, "Richard Quinton" richard.quinton63@gmail.com, "Luca Giovanelli" luca.giovanelli@unimi.it, "Luca Persani" luca.persani@unimi.it, "Marco Bonomi" m.bonomi@auxologico.it

Dear Dr. Cangiano:

The editors and reviewers have completed their review of your manuscript, "New and consolidated therapeutic options for pubertal induction: in-depth review of the literature", er.2021-00117R1. It has been accepted for publication and scheduled to appear in an upcoming issue of *Endocrine Reviews*.

Your manuscript will next be sent to production. You will be asked to select and sign your license in an email that will come from Oxford University Press (OUP) and after that step is completed, an unedited version of your manuscript will post as an Advance Article on the journal site within seven working days. No changes can be made to the Advance Article version. As your article progresses through the production process, you will receive emails from our typesetter, Newgen, as well as our publisher, OUP. These messages may require action from you. Within three weeks you'll receive a proof to be returned within 24 hours with your corrections. If you have any questions or concerns about any aspect of the process, please contact jnl.author.support@oup.com.

Please note that your manuscript submission files are now considered finalized. While minor corrections may be made during the proof stage, any changes to the author byline, data, figures, tables, or additions of erroneously omitted files will delay production and require editorial approval. If you have any questions or concerns about this policy, please contact jnl.author.support@oup.com.

If you have posted data to a repository that only releases permanent links after manuscript acceptance (such as Dryad), you will have the opportunity to update the links when you receive your author proof. Please update your repository information at that time.


Figures supplied by the author are redrawn by professional illustrators. These figures will maintain a consistent visual style and will be ideal for use as educational slides.

If you have indicated that you received NIH funding, note that the Endocrine Society will submit your final edited manuscript to PubMed Central on your behalf. This will fulfill your obligation to deposit your work as required by the NIH Public Access Policy. The identification number needed for reporting the publication - the PMCID - will be available as part of your abstract on PubMed approximately two weeks after final publication.

The Associate Editors and I appreciate the work you have put into this manuscript and look forward to having it appear in *Endocrine Reviews*.



Congratulations!

Daniel J. Drucker, MD
Editor-in-Chief, *Endocrine Reviews*
publications@endocrine.org



[Click here to access/download](#)

Revised Manuscript - Changes Highlighted
Letter to the Editor_REV_marked-up.docx



Letter to the Editor From [Giovanelli] et al.: “DISTINGUISHING SELF-LIMITED DELAYED PUBERTY FROM PERMANENT HYPOGONADOTROPIC HYPOGONADISM: HOW AND WHY?”

Luca Giovanelli ^{1,2} & Richard Quinton ^{3,4}

¹ *Department of Medical Biotechnology and Translational Medicine, University of Milan, 20100 Milan, Italy*

² *Department of Endocrine and Metabolic Medicine, IRCCS Istituto Auxologico Italiano, 20100 Milan, Italy*

³ *Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals, NE1 4LP, UK*

⁴ *Translational & Clinical Research Institute, University of Newcastle-upon-Tyne, NE1 3BZ, UK*

DISCLOSURE STATEMENT: LG has nothing to declare. RQ has received speaker honoraria and conference sponsorship from Bayer-UK and Besins UK.

It is oft repeated how challenging it can be to distinguish between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) in adolescents with delayed puberty (DP). Although these conditions share several clinical, biochemical and radiological features, they diverge widely in management and outcomes: CDGP is self-limiting and may need no treatment, whereas CHH requires prompt intervention to induce or complete pubertal development and mitigate adverse psychosexual and mental health outcomes [1,2].

In their article, Harrington and Palmert [3] highlight persistent shortcomings in this area and focus on the most newly proposed diagnostic tests, encompassing kisspeptin-stimulated LH levels and FSH-stimulated inhibin B concentrations. Although these advances appear promising, the authors fail to emphasize other important measures, such as the evaluation of pre-test probability and the value of Bayesian analysis in determining management.

There is facile assumption that CDGP is the more common condition, but this assumes clinical presentation in early-mid teenage years and the absence of characteristic reproductive and non-reproductive clinical phenotypes - labelled as “red flags” - that are far more prevalent in CHH than in CDGP [1]. However, in older teenagers, or those having one or more red flag features, CDGP becomes the least likely diagnosis. In boys, neonatal cryptorchidism (especially when bilateral) and micropallus may indicate CHH-related absent mini-puberty [4]. Non-reproductive hallmarks include anosmia (*i.e.* Kallmann syndrome), craniofacial clefting, deafness, digital abnormalities, dental agenesis, renal aplasia and neurologic anomalies such as synkinesis (mirror movements).

Notably, a retrospective web-based study of “all-comers” with CHH [5] showed pubertal induction was undertaken at the median age of 18 ± 6 years in males and 19 ± 5 years in females, with clinicians’ inexplicable blindness to obvious “red flags” being one of the core reasons behind this unacceptable delay.

The age at presentation is another key point overlooked by the authors [3]; whilst among younger teenagers, at least 30% of girls and up to 65% of boys with DP have CDGP [6,7], pathological forms of hypogonadism become exponentially more likely with increasing age; becoming the default diagnosis beyond 18–20 years, or indeed when linear growth is preserved.

In conclusion, we commend the authors for turning the spotlight on the novel developments regarding differential diagnosis of DP, which represents to date a tricky challenge. Indeed, the failure to distinguish between CHH and CDGP can lead to crippling psychological discomfort among patients and their caregivers [5,8].

We also wish to highlight the role of Bayesian logic, which is underutilised in the biosciences, whereby the absolute probability of a finding being true or false is tempered by knowledge of the likely consequences of false-positive and false-negatives. For teenagers with CHH, the adverse

consequences of a false-negative diagnosis (of CDGP) last for decades, whereas for those with CDGP it is hard to perceive any meaningful adverse outcomes arising from a false-positive CHH diagnosis, leading to treatment that is eventually set aside few years' later.

References

- 1) Federici S, Goggi G, Quinton R, Giovanelli L, Persani L, Cangiano B, Bonomi M. New and consolidated therapeutic options for pubertal induction in hypogonadism: in-depth review of the literature. *Endocrine Reviews* (*in press*)
- 2) Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin JP, Juul A, Maghnie M, Pitteloud N, Prevot V, Raivio T, Tena-Sempere M, Quinton R, Young J. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. *Nat Rev Endocrinol*. 2015 Sep;11(9):547-64.
- 3) Harrington J, Palmert MR. Distinguishing Self-limited Delayed Puberty from Permanent Hypogonadotropic Hypogonadism: How and Why? *J Clin Endocrinol Metab*. 2021 Jul 5:dgab498.
- 4) Persani L, Bonomi M, Cools M, Dattani M, Dunkel L, Gravholt CH, Juul A. ENDO-ERN expert opinion on the differential diagnosis of pubertal delay. *Endocrine*. 2021 Mar;71(3):681-688.
- 5) Dwyer AA, Tiemensma J, Quinton R, Pitteloud N, Morin D. Adherence to treatment in men with hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf)*. 2017 Mar;86(3):377-383.
- 6) Dunkel L, Quinton R. Transition in endocrinology: induction of puberty. *Eur J Endocrinol*. 2014 Jun;170(6):R229-39.
- 7) Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamäki J, Raivio T, Pitteloud N. Clinical Management of Congenital Hypogonadotropic Hypogonadism. *Endocr Rev*. 2019 Apr 1;40(2):669-710.
- 8) Swee DS, Quinton R. Managing congenital hypogonadotropic hypogonadism: a contemporary approach directed at optimizing fertility and long-term outcomes in males. *Ther Adv Endocrinol Metab*. 2019 Feb 10;10:2042018819826889.